Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis

• Status: Unknown status
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The goal of the pilot study is to determine if a multicenter prospective cohort study of cancer patients with blood clots associated with catheters is feasible. Cancer patients with catheter-related thrombosis treated with one month of anticoagulation will be evaluated for for post-thrombotic syndrome. Laboratory biomarkers will be evaluated as predictors of recurrent thrombosis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical College of Wisconsin
• Collaborators: Blood Center of Wisconsin; Ohio State University; University of Minnesota - Clinical and Translational Science Institute; Versiti
• Treatments: Anticoagulants; Apixaban; Calcium heparin; Dabigatran; Dalteparin; Edoxaban; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Rivaroxaban; Tinzaparin

Criteria

Inclusion Criteria:

• Upper extremity venous thrombosis associated with an indwelling catheter documented by ultrasound, CT or venography

• Current hematologic or solid tumor malignancy undergoing chemotherapy, surgery, radiation or hormonal therapy for malignancy.

• >18 years of age

• Platelet count >50,000

• Creatinine clearance >30 ml/min

• Ability to provide informed consent

Exclusion Criteria:

• Underlying medical condition or chemotherapy requiring long-term anticoagulation

• Known underlying higher risk thrombophilias including antiphospholipid antibody syndrome, antithrombin, protein C or protein S deficiencies, or homozygosity or compound heterozygosity for prothrombin G20210A or Factor V R506Q mutations.

• Inability to remove venous catheter

• Anticipated replacement of central venous catheter within 3 months

• Major bleeding or clinically relevant non-major bleeding in the preceding 60 days

• Participation in another clinical trial that requires anticoagulation

• Use of anticoagulant other than low-molecular weight heparin

• Treatment with thrombolysis

• Catheter removal >1 month prior to enrollment